Strontium-89 chloride for pain palliation in prostatic skeletal malignancy.

Abstract

In a multi-centre study strontium-89 was shown to be effective in relieving bone pain from prostatic carcinoma in patients who had failed conventional therapies. Of 83 patients assessed at 3 months, following the administration of a dose of at least 1.5 MBq/kg, 75% derived benefit and 22% became pain free. Symptomatic improvement usually occurred within 6 weeks and continued for between 4 and 15 months (mean 6 months). Based on the dose estimation part of this study the recommended dose of strontium-89 is 150 MBq. Toxicity was low, provided platelet levels were above 100 x 10(9) l-1 at the time of treatment. Repeat treatments with strontium-89 may be given at intervals of not less than 3 months. Strontium-89 is administered intravenously on an out-patient basis with no special radiological protection precautions.

• Authors: A H Laing, D M Ackery, R J Bayly, R B Buchanan, V J Lewington, A J McEwan, P M Macleod, M A Zivanovic
• Journal: The British journal of radiology (Br J Radiol) Vol. 64 Issue 765 Pg. 816-22 (Sep 1991) ISSN: 0007-1285 [Print] England
• PMID: 1717094 (Publication Type: Clinical Trial, Journal Article, Multicenter Study)

Chemical References

• Strontium Radioisotopes
• strontium chloride
• Strontium

Topics

• Bone Neoplasms (pathology, radiotherapy, secondary)
• Humans
• Male
• Palliative Care (methods)
• Platelet Count (radiation effects)
• Prostatic Neoplasms (pathology)
• Radiotherapy Dosage
• Strontium (therapeutic use)
• Strontium Radioisotopes (therapeutic use)